IN2015DN01371A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01371A
IN2015DN01371A IN1371DEN2015A IN2015DN01371A IN 2015DN01371 A IN2015DN01371 A IN 2015DN01371A IN 1371DEN2015 A IN1371DEN2015 A IN 1371DEN2015A IN 2015DN01371 A IN2015DN01371 A IN 2015DN01371A
Authority
IN
India
Prior art keywords
ifn
fusion protein
present
protein
interferon
Prior art date
Application number
Other languages
English (en)
Inventor
Yong Soo Bae
Seung Ho Hong
Young Hoon Kim
Seung Soo Han
Jin Kim
Original Assignee
Jw Creagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jw Creagene Inc filed Critical Jw Creagene Inc
Publication of IN2015DN01371A publication Critical patent/IN2015DN01371A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN1371DEN2015 2012-08-13 2013-08-07 IN2015DN01371A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120088610 2012-08-13
PCT/KR2013/007136 WO2014027789A1 (ko) 2012-08-13 2013-08-07 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질

Publications (1)

Publication Number Publication Date
IN2015DN01371A true IN2015DN01371A (enExample) 2015-07-03

Family

ID=50685640

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1371DEN2015 IN2015DN01371A (enExample) 2012-08-13 2013-08-07

Country Status (6)

Country Link
US (1) US9682152B2 (enExample)
JP (1) JP6010227B2 (enExample)
KR (1) KR102012025B1 (enExample)
CN (1) CN104583240B (enExample)
IN (1) IN2015DN01371A (enExample)
WO (1) WO2014027789A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987381B (zh) * 2015-06-11 2018-11-27 吉林大学 重组正电荷多肽干扰素及在抗肿瘤和抗病毒治疗中的应用
WO2021062181A1 (en) * 2019-09-26 2021-04-01 Orionis Biosciences, Inc. Conjugated chimeric proteins
KR20230099956A (ko) * 2021-12-28 2023-07-05 제이더블유크레아젠 주식회사 면역세포에 항원을 전달하기 위한 폴리펩타이드
CN114853911B (zh) * 2022-05-23 2024-06-28 复旦大学 三叶因子2/干扰素α2融合蛋白及其防治病毒感染性疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441661T1 (de) * 2002-03-29 2009-09-15 Creagene Inc Zytoplasmatische transduktionspeptide und deren verwendungen
RU2008109649A (ru) * 2005-08-15 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
KR101183826B1 (ko) * 2009-03-27 2012-09-18 제이더블유중외제약 주식회사 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
CN101942026B (zh) * 2010-10-14 2014-08-27 成都正能生物技术有限责任公司 长效干扰素融合蛋白及其用途

Also Published As

Publication number Publication date
CN104583240A (zh) 2015-04-29
KR102012025B1 (ko) 2019-08-19
JP6010227B2 (ja) 2016-10-19
JP2015526084A (ja) 2015-09-10
US20150202312A1 (en) 2015-07-23
KR20150063375A (ko) 2015-06-09
US9682152B2 (en) 2017-06-20
WO2014027789A1 (ko) 2014-02-20
CN104583240B (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
NZ749962A (en) Pegylated porcine interferon and methods of use thereof
CR20200196A (es) Proteínas trispecìficas y mètodos de uso
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MY196882A (en) Recombinant binding proteins and their use
IL212184A (en) Conditional expression vector of protein (s) acting as immunomodulator (s), engineered training cells, their pharmaceutical composition and their use in drug preparation
MX388977B (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso.
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
EP3500304A4 (en) USE OF A BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN THE MANUFACTURE OF ANTITUMUMPRODUCTIVE MEDICAMENT
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
PH12017500450A1 (en) Flavivirus virus like particle
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
IN2014DN03213A (enExample)
IN2015DN01371A (enExample)
EP3362048A4 (en) COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
IN2014CN00510A (enExample)
BR112014028951A2 (pt) peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos
EA201491991A1 (ru) Новая система высвобождения гидрофобных белков
MX2021001361A (es) Composicion liquida de fibrinogeno humano.